Experimental study on inhibition of alveolar bone resorption around periodontitis in rats by cyclocreatine

doi:10.19438/j.cjoms.2022.02.002

Abstract

Abstract: PURPOSE: To evaluate the inhibitory effect of cyclocreatine on alveolar bone resorption caused by periodontitis both in vitro and in vivo. METHODS: In vitro, the effects of cyclocreatine on proliferation and differentiation of osteoblasts and osteoclasts were evaluated by cell viability assay, alkaline phosphatase staining (ALP) and alizarin red staining, tartrate resistant acid phosphatase (TRAP) staining and real-time reverse transcription PCR (RT-PCR). Twenty rats were divided into four groups, group A was as control group, group B with periodontal ligation + normal saline injection, group C with periodontal ligation + low concentration injection, group D with periodontal ligation + high concentration injection. Except the control group, all rats were ligated on bilateral maxillary first molars for 4 weeks, and then treated with local injection of cyclocreatine for 2 months. The maxilla was collected for further Micro-CT evaluation. SPSS 16.0 software package was used for statistical analysis of the data. RESULTS: In vitro, cyclocreatine inhibited the proliferation and differentiation of osteoclasts, but did not affect osteoblasts. In vivo, local application of cyclocreatine can prevent local alveolar bone loss and increase alveolar ridge height. CONCLUSIONS: Cyclocreatine can inhibit proliferation and differentiation of osteoclasts, inhibit formation of osteoclasts and reduce alveolar bone loss in rat with periodontitis.

Key words: Cyclocreatine, Periodontitis, Alveolar defects, Rat

CLC Number:

R782.1

LI Hui-ping, LIU Xiu-ming, XU Wei-feng, ZHEN Jin-ze, SHEN Da, ZHANG Shan-yong. Experimental study on inhibition of alveolar bone resorption around periodontitis in rats by cyclocreatine[J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(2): 111-116.

References

[1] Teicher BA, Menon K, Northey D, et al.Cyclocreatine in cancer chemotherapy[J]. Cancer Chemother Pharmcol, 1995, 35(5): 411-416.
[2] Houser SL, Elkerm AF, Wei Z, et al.Enhancement of cardiac function by Cyclocreatine in models of cardiopulmonary bypass[J]. J Mol Cell Cardiol, 1995, 27(4): 1065-1073.
[3] Cekici A, Kantarci A, Hasturk H.Inflammatory and immune pathways in the pathogenesis of periodontal disease[J]. Periodontol 2000, 2014, 64(1): 57-80.
[4] Hienz SA, Paliwal S, Ivanovski S.Mechanisms of bone resorption in periodontitis[J]. J Immunol Res, 2015: 615486.
[5] Chang EJ, Ha J, Oerlemans F, et al.Brain-type creatine kinase has a crucial role in osteoclast-mediated bone resorption[J]. Nat Med, 2008, 14(9): 966-972.
[6] Page RC, Ofenbacher S, Schroeder HE, et al.Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions[J]. Periodontol 2000, 1997, 14(7): 216-248.
[7] Molon RS, de Avila ED, Cirelli JA. Host responses induced by different animal models of periodontal disease: a literature review[J]. J Investig Clin Dent, 2013, 4(4): 221-218.
[8] de Molon RS, Park CH, Jin Q, et al. Characterization of ligature-induced experimental periodontitis[J]. Microsc Res Tech, 2018, 81(12): 1412-1421.
[9] de Molon RS, Cheong S, Bezouglaia O, et al. Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model[J]. Bone, 2014, 68: 11-19.
[10] de Souza JA, Nogueira AV, de Souza PP, et al. Expression of suppressor of cytokine signaling 1 and 3 in ligature-induced periodontitis in rats[J]. Arch Oral Biol, 2011, 56(10): 1120-1128.
[11] Chen J, Sun Y, Mao X, et al.RANKL up-regulates brain-type creatine kinase via poly(ADP-ribose) polymerase-1 during osteoclastogenesis[J]. J Biol Chem, 2010, 285(47): 36315-36321.
[12] Murata K, Fang C, Terao C, et al.Hypoxia-sensitive COMMD1 integrates signaling and cellular metabolism in human macrophages and suppresses osteoclastogenesis[J]. Immunity, 2017, 47(1): 66-79.
[13] Ulland TK, Song WM, Huang SC, et al. TREM2 maintains microglial metabolic fitness in alzheimer's disease[J]. Cell, 2017, 170(4): 649-663.e13.
[14] Uemura T, Ito S, Masuda T, et al.Cyclocreatine transport by SLC6A8, the creatine transporter, in HEK293 cells, a human blood-brain barrier model cell, and CCDSs patient-derived fibroblasts[J]. Pharm Res, 2020, 37(3): 61-72.
[15] Cacciante F, Gennaro M, Sagona G, et al.Cyclocreatine treatment ameliorates the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter deficiency[J]. Sci Rep, 2020, 10(1): 18361.